Clinical Trials Logo

Cryoglobulinemia Vasculitis clinical trials

View clinical trials related to Cryoglobulinemia Vasculitis.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT00574652 Completed - Clinical trials for Cryoglobulinemia Vasculitis

Evaluation of Clinical Efficacy and Immunologic Response After IL-2 Therapy in HCV-related Vasculitis Patients

Start date: March 2008
Phase: Phase 1/Phase 2
Study type: Interventional

A systemic Vasculitis is found in 5 to 10% of HCV infected patients with mixed cryoglobulinemia (MC). It mainly involves the skin, peripheral nerve and the kidney and may be life threatening. Twenty to 30% of HCV-MC Vasculitis patients are resistant to conventional therapy (i.e. antiviral therapy and/or immunosuppressors) and still have an active disease. Thus, new therapeutic approaches are necessary in such patients. We recently described a regulatory T cell (Treg) deficiency in HCV-related Vasculitis patients. Immunomodulatory effects of interleukin-2 (IL-2) are well established, notably the preferential expansion of Treg able to suppress inflammatory responses mediated by CD4+ and CD8+ T cells.